Search results
University College London School of Pharmacy - Cited by 2,440 - Pharmaceutics - Pulmonary Drug Delivery
Studies investigating RNA therapeutics in pulmonary diseases have rapidly expanded and drug administration by inhalation allows the direct delivery of RNA therapeutics to the target site of action while minimizing systemic exposure.
- Michael Y.T. Chow, Michael Y.T. Chow, Yingshan Qiu, Jenny K.W. Lam
- 2020
Michael Y.T. Chow's 33 research works with 1,650 citations and 21,161 reads, including: Delivery technology of inhaled therapy for asthma and COPD
This chapter provides an overview of inhaled therapy for the management of asthma and COPD. The operation principles, merits and limitations of different delivery technologies are examined. Looking ahead, the challenges of delivering novel therapeutics such as biologics through the pulmonary route are also discussed.
Michael Y.T. Chow,1,2,3 Yingshan Qiu,1,3 and Jenny K.W. Lam1,* RNA-based medicine is receiving growing attention for its diverse roles and potential therapeutic capacity. The largest obstacle in its clinical translation re-mains identifying a safe and effective delivery system.
Sep 4, 2020 · Abstract. RNA-based medicine is receiving growing attention for its diverse roles and potential therapeutic capacity. The largest obstacle in its clinical translation remains identifying a safe and effective delivery system.
Mar 2, 2015 · SD siRNA powders containing pH-responsive peptides are a promising inhalable formulation to deliver antiviral siRNA against influenza and are readily adapted for the treatment of other respiratory diseases.
